Developing science,
delivering therapies


Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more


4D pharma plc announces the appointment of John Doyle as Chief Financial Officer (CFO). Mr. Doyle brings over 15 years of experience leading and developing the financial operations, strategy and investor relations functions at public healthcare companies.
Part A of the study meets primary endpoint of safety and tolerability MRx-4DP0004 also achieved multiple key secondary endpoints relating to improved asthma control compared to placebo
Results demonstrate changes in gut microbiome structure following administration of Blautix in both IBS-C and IBS-D patients